These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33544482)

  • 1. The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency.
    Abildgaard A; Hvas AM
    Clin Chem Lab Med; 2021 Jun; 59(7):e297-e300. PubMed ID: 33544482
    [No Abstract]   [Full Text] [Related]  

  • 2. Coagulation studies in a case of severe congenital hypofibrinogenemia.
    Barbu T; Porciello PI; Dini E
    Thromb Diath Haemorrh; 1972 Aug; 28(1):129-34. PubMed ID: 4627565
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrinogen Clauss and prothrombin time derived method ratio can differentiate dysfibrinogenemia from hypofibrinogenemia and hyperfibrinogenemia.
    Luo M; Xiang L; Yan J; Liao L; Wu Y; Deng X; Deng D; Cheng P; Lin F
    Thromb Res; 2020 Oct; 194():197-199. PubMed ID: 32788118
    [No Abstract]   [Full Text] [Related]  

  • 4. Preanalytical Variables on Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen.
    Joob B; Wiwanitkit V
    Clin Lab; 2016 Jul; 62(7):1379. PubMed ID: 28164643
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia.
    Ross CR; Subramanian S; Navarro-Puerto J; Subramanian K; Kalappanavar NK; Khayat CD; Acharya SS; Peyvandi F; Rucker K; Liang W; Vilardell D; Trimm S; Ayguasanosa J
    Thromb Res; 2021 Mar; 199():110-118. PubMed ID: 33486319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital afibrinogenemia in Hasan Sadikin Hospital.
    Supandiman I; Sumantri R
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():267-9. PubMed ID: 7886594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method.
    Llamas P; Santos AB; Outeiriño J; Soto C; Tomás JF
    Thromb Res; 2004; 114(1):73-4. PubMed ID: 15262488
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prothrombin time, activated partial thromboplastin time, plasma fibrinogen determination. Comparison of two automated coagulation systems: Koagulab 40-A and ACL-100].
    Barbe D; Bauduer F; Tanguy A
    Ann Biol Clin (Paris); 1991; 49(10):507-13. PubMed ID: 1807170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.
    Prieto JA; Mastrobattista JM; Blanco JD
    Am J Perinatol; 1995 May; 12(3):220-2. PubMed ID: 7612100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital afibrinogenemia. A case report with some considerations on the hereditary transmission of this disorder.
    Girolami A; Zacchelo G; D'Elia R
    Thromb Diath Haemorrh; 1971 Jun; 25(3):460-8. PubMed ID: 5561958
    [No Abstract]   [Full Text] [Related]  

  • 11. Early coagulopathy at hospital admission predicts initial or delayed fibrinogen deficit in severe trauma patients.
    Deras P; Villiet M; Manzanera J; Latry P; Schved JF; Capdevila X; Charbit J
    J Trauma Acute Care Surg; 2014 Sep; 77(3):433-40. PubMed ID: 25159247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation quality control surveys in France.
    Goguel AF; Houbouyan LL; Roussi JH
    Scand J Haematol Suppl; 1980; 37():150-2. PubMed ID: 6941434
    [No Abstract]   [Full Text] [Related]  

  • 13. [Blood coagulation tests ].
    Fukue H; Fukutake K
    Rinsho Byori; 1997 Nov; Suppl():99-106. PubMed ID: 9508613
    [No Abstract]   [Full Text] [Related]  

  • 14. [EVALUATION OF METHODS FOR THE DETERMINATION OF THE PROTHROMBIN COMPLEX ACTIVITY].
    MARES J; PODLIPNY J
    Z Arztl Fortbild (Jena); 1964 Jun; 58():709-13. PubMed ID: 14240434
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory.
    de Metz M; van Wersch JW
    Haemostasis; 1987; 17(5):254-9. PubMed ID: 3666583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults.
    Miljic D; Miljic P; Doknic M; Pekic S; Djurovic M; Colovic M; Popovic V
    Hormones (Athens); 2006; 5(3):187-91. PubMed ID: 16950752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and safety of a novel fibrinogen concentrate in pediatric patients with congenital afibrinogenemia.
    Khayat CD; Navarro-Puerto J; Ross CR; Subramanian K; Kalappanavar NK; Rucker K; Liang W; Mondou E
    Blood Coagul Fibrinolysis; 2023 Jan; 34(1):61-69. PubMed ID: 36484281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the automated coagulation analyzer SYSMEX CA 6000.
    Quehenberger P; Kapiotis S; Handler S; Ruzicka K; Speiser W
    Thromb Res; 1999 Oct; 96(1):65-71. PubMed ID: 10554086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated clot-based methods in coagulation testing: current and future considerations.
    Walenga JM; Hoppensteadt D; Fareed J; Silberman S; Shelvin P
    Semin Thromb Hemost; 1983 Oct; 9(4):245-9. PubMed ID: 6658458
    [No Abstract]   [Full Text] [Related]  

  • 20. Abnormal fibrinogens. A review.
    Ménaché D
    Thromb Diath Haemorrh; 1973 Jun; 29(3):525-35. PubMed ID: 4586807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.